SAUDI FELLOWSHIP TRAINING PROGRAM

CLINICAL PHARMACY SOLID ORGAN TRANSPLANTATION

Final Examination

Exam Format:
A Saudi subspecialty fellowship final written examination shall consist of one paper with 80-120 Single Best Answer MCQs. 10% unscored items can be added for pretesting purposes.

Passing Score:
The passing score is 70%. However, if the percentage of candidates passing the examination before final approval is less than 70%, the passing score must be lowered by one mark at a time aiming at achieving 70% passing rate or 65% passing score whichever comes first. Under no circumstances can the passing score be reduced below 65%.
Blueprint Outline:

<table>
<thead>
<tr>
<th>No.</th>
<th>Sections</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Pretransplant</td>
<td>15%</td>
</tr>
<tr>
<td>2</td>
<td>Perioperative</td>
<td>20%</td>
</tr>
<tr>
<td>3</td>
<td>Post-transplant</td>
<td>30%</td>
</tr>
<tr>
<td>4</td>
<td>Graft dysfunction</td>
<td>10%</td>
</tr>
<tr>
<td>5</td>
<td>Immunosuppression</td>
<td>15%</td>
</tr>
<tr>
<td>6</td>
<td>Ambulatory care</td>
<td>10%</td>
</tr>
</tbody>
</table>

Total 100%

Solid Organ Transplantation includes liver (45%); kidney (45%); heart, lung, pancreas and islet cell and small bowel or combination of 2 or more organs (10%)

1 Pretransplant: including indications and contraindications and candidacy of transplantation; screening of donors and recipients; transplant immunology; prophylaxis of infections.

(laboratory testing and immunizations)

2 Perioperative: including perioperative complications (donor and recipients); management of patients and donors pre- and immediately after transplant in ICU; prophylaxis and management of rejection; prophylaxis of infections (viral, bacterial, mycobacterial, parasitic and fungal)

3 Post-transplant including but not limited to: non infectious, infectious, graft dysfunction, management of acute and chronic rejection (cellular and humoral); immunosuppressive medications and immunizations; infectious diseases prevention and management (bacterial, viral fungal, mycobacterial, parasitic infections); post-transplant complications (short and long term complications including but not limited to cardiovascular, chronic diseases, endocrine, CNS, post-transplant lymphoproliferative disease(PTLD)); adherence to medical regimen; recurrence of disease; post-transplant malignancy and indications for re-transplantation.

4 Ambulatory care including but not limited to post transplant care, management of immunosuppression’s, common infectious diseases, common comorbidities.
Notes:

- Blueprint distributions of the examination may differ up to +/-5% in each section.
- Percentages and content are subject to change at any time. See the SCFHS website for the most up-to-date information.
- Research, Ethics, Professionalism, and Patient Safety are incorporated within various domains.

Suggested References:

2. The most recent American Society of Transplantation (AST) guidelines published by the American Journal of Transplantation (AJT)
3. The International Society for Heart and Lung Transplantation Clinical Practice updated Guidelines
4. The American association for study liver disease Clinical Practice updated Guidelines
5. The European association for study liver disease Clinical Practice updated Guidelines
6. The Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice updated Guidelines
Note:

This list includes latest published guidelines before July 2023, and it is intended for use as a study aid only. SCFHS does not intend the list to imply endorsement of these specific references, nor are the exam questions necessarily taken solely from these sources.